Abbott Study on ctDNA and Colorectal Cancer Recurrence

Abbott ran the study in collaboration with the National Cancer Center Hospital East in Japan.

The study paired pretreatment comprehensive genomic profiling using Guardant360 Liquid with postoperative molecular residual disease testing using Guardant Reveal, administered approximately four weeks after surgery.

Additional findings showed Guardant360 Liquid detected genomic alterations in 97 percent of patients, with 64 percent carrying profiles associated with more than a fourfold higher hazard of recurrence or death. Postoperative MRD was evaluable in 99 percent of surgical patients, with MRD detected in 31 percent of patients and associated with a 4.7-fold increase in hazard of recurrence or death.

He added that the findings “should be prospectively verified in an interventional study.”

Separately, a study published in the Journal of the American College of Surgeons on November 17, 2026 examined whether rectal cancer patients actually receive guideline-recommended staging before surgery.

Authored by Calista M Harbaugh, Clare E Jacobson, Nicholas Kunnath and colleagues at the Center for Healthcare Outcomes and Policy, Institute for Healthcare Policy and Innovation, and the Department of Surgery at the University of Michigan, the retrospective observational study used 100 percent Medicare claims to identify patients aged 65–99 years undergoing elective proctectomy for rectal cancer between 2016 and 2023.

The broader evidence base for ctDNA in colorectal cancer remains in flux.

Tumour-agnostic assays have nonetheless shown prognostic value in large stage III datasets.

Strategy trials testing whether ctDNA-guided treatment decisions improve outcomes have been mixed. The COBRA/NRG-GI005 trial in the United States, a phase II/III strategy trial in low-risk stage IIA colon cancer, stopped its phase II for futility after 16 ctDNA-positive patients when the postoperative 6-month ctDNA clearance endpoint was not improved by chemotherapy.

DYNAMIC-III, a randomised strategy trial of stage III colon cancer in Australia, New Zealand and Canada, found that de-escalation reduced oxaliplatin but did not meet non-inferiority, while escalation did not improve recurrence-free survival in ctDNA-positive disease.

One review of the field, covering literature published from January 1, 2016, to July 31, 2026, searched PubMed/MEDLINE, ClinicalTrials.gov, and the abstract databases of ASCO, ESMO, and the ESMO Gastrointestinal Cancers Congress using combinations of terms including “circulating tumour DNA”, ctDNA, “molecular residual disease”, “colorectal”, “adjuvant”, and “surveillance”.

Its caveats are straightforward: a negative result does not mean absence of residual disease, and a negative strategy trial can reflect the assay, sampling schedule, treatment algorithm, or intervention — not necessarily the entire biomarker concept.

Competing-interest disclosures in the published study are extensive.

>
Photo of author

Health Desk

Health Desk at Archyde.

Tongji Team Maps FGF19 Pathway as Guardian or Destroyer in Liver

San Diego Studio Reveals MLB The Show 27 After Tough Year